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Abstract
VEGF121/rGel, a fusion protein composed of the growth
factor VEGF121 and the recombinant toxin gelonin
(rGel), targets the tumor neovasculature and exerts
impressive cytotoxic effects by inhibiting protein syn-
thesis. We evaluated the effect of VEGF121/rGel on the
growth of metastatic MDA-MB-231 tumor cells in SCID
mice. VEGF121/rGel treatment reduced surface lung
tumor foci by 58% compared to controls (means were
22.4 and 53.3, respectively;P < .05) and themean area of
lung colonies by 50% (210 ± 37 m2 vs 415 ± 10 m2 for
VEGF121/rGel and control, respectively; P < .01). In
addition, the vascularity of metastatic foci was signifi-
cantly reduced (198 ± 37 vs 388 ± 21 vessels/mm2 for
treated and control, respectively). Approximately 62%
of metastatic colonies from the VEGF121/rGel–treated
group had fewer than 10 vessels per colony compared
to 23% in the control group. The VEGF receptor Flk-1
was intensely detected on the metastatic vessels in the
control but not in the VEGF121/rGel–treated group.
Metastatic foci present in lungs had a three-fold lower
Ki-67 labeling index compared to control tumors. Thus,
the antitumor vascular-ablative effect of VEGF121/rGel
may be utilized not only for treating primary tumors but
also for inhibiting metastatic spread and vasculariza-
tion of metastases.
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Introduction
Biologic studies examining the development of vascular
tree in normal development and in disease states have
identified numerous cytokines and their receptors that are
responsible for triggering and maintaining this process
[1–7]. Tumor neovascularization is not only central to the
growth and development of the primary lesion, but appears
to be a critical factor in the development and maintenance
of metastases [8–12]. Clinical studies in bladder cancer [9]
have demonstrated a correlation between microvessel den-
sity (MVD) and metastases. In addition, studies of breast can-
cer metastases by Aranda and Laforga [11] and Fox et al. [12]
have demonstrated that microvessel count in primary tumors
appears to be related to the presence of metastases in lymph
nodes and micrometastases in bone marrow.
The cytokine vascular endothelial growth factor-A (VEGF-A)
and its receptors Flt-1/FLT-1 (VEGFR-1) and Flk-1/KDR
(VEGFR-2) have been implicated as one of the central medi-
ators of normal angiogenesis and tumor neovascularization
[13–20]. Upregulation or overexpression of the KDR receptor
or the VEGF-A ligand itself has been implicated as poor
prognostic markers in various clinical studies of colon, breast,
and pituitary cancers [21–23]. Recently, Padro et al. [24] have
suggested that both VEGF-A and Flk-1/KDR may play a role
in the neovascularization observed in bone marrow during
acute myeloid leukemia tumor progression and may provide
evidence that the VEGF/VEGFR-2 pathway is important in
leukemic growth.
For these reasons, there have been several groups inter-
ested in developing therapeutic agents and approaches tar-
geting the VEGF-A pathway. Agents that prevent VEGF-A
binding to its receptors, antibodies that directly block the Flk-1/
KDR receptor, and small molecules that block the kinase
activity of Flk-1/KDR, and thereby block growth factor signal-
ing, are all under development [25–37]. Recently, our labo-
ratory reported the development of a growth factor fusion
construct of VEGF121 and the recombinant toxin gelonin
(rGel) [38]. The rGel toxin is a single-chain N-glycosidase
that is similar in its action to ricin-A chain [39]. Immuno-
toxins and fusion toxins containing rGel have been shown to
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specifically kill tumor cells in vitro and in vivo [40–43]. In
currently ongoing clinical studies, gelonin does not appear to
generate vascular leak syndrome (VLS) that limits the use of
other toxins [44]. In addition, the development of hepatotox-
icity commonly observed with toxin molecules has thus far
not been observed for rGel-based agents. Our studies dem-
onstrated that this agent was specifically cytotoxic only to
cells expressing the KDR receptor and was not cytotoxic to
cells overexpressing the FLT-1 receptor. In addition, this
agent was shown to localize within the tumor vasculature
and caused a significant damage to the vascular endothe-
lium in both PC-3 prostate and A375 orthotopic xenograft
tumor models.
There is now a significant body of evidence suggesting
that breast tumor development, differentiation, and meta-
static spread appear to be critically dependent on tumor
neovascularization. Current studies suggest that the de-
velopment of breast cancer primary tumors or metastatic
sites > 2 mm are critically dependent on the growth of
tumo neovasculature. We, therefore, evaluated the effect
of VEGF121/rGel fusion toxin treatment on the growth of
metastatic MDA-MB-231 tumor cells in SCID mice. Our
data strongly suggest that the vascular-ablative effect of
VEGF121/rGel may be used for inhibiting metastatic spread
and the vascularization of metastases.
Materials and Methods
Materials
Bacterial strains, pET bacterial expression plasmids, and
recombinant enterokinase were obtained from Novagen
(Madison, WI). All other chemicals were from Sigma Chemi-
cal Co. (St. Louis, MO) or Fisher Scientific (Pittsburgh, PA).
TALON metal affinity resin was obtained from Clontech
Laboratories (Palo Alto, CA). Other chromatography resins
and materials were from Amersham Pharmacia Biotech (Pis-
cataway, NJ). Endothelial cell growth supplement (ECGS)
from bovine neural tissue was obtained from Sigma. Murine
brain endothelioma (bEnd.3) cells were provided by Profes-
sor Werner Risau (Max Plank Institute, Munich, Germany).
Tissue culture reagents were fromGibco BRL (Gaithersburg,
MD) or Mediatech Cellgro (Herndon, VA).
Antibodies
Rat antimouse CD31 antibody was from PharMingen
(San Diego, CA). Rabbit antigelonin antibody was produced
in the Veterinary Medicine Core Facility at MDACC. The
hybridoma producing the mouse monoclonal w6/32 antibody
directed against human HLA antigen was purchased from
ATCC. The w6/32 antibody was purified from hybridoma
supernatant using protein A resin. MECA 32, a pan mouse
endothelial cell antibody, was kindly provided by Dr. E.
Butcher (Stanford University, Stanford, CA) and served as
a positive control for immunohistochemical studies. The
Ki-67 antibody was from Abcam, Inc. (Cambridge, UK).
Antibodies to KDR and FLT-1 were from Santa Cruz Bio-
technology (Santa Cruz, CA). Goat antirat, antimouse, and
antirabbit secondary antibodies conjugated to HRP were
purchased fromDako (Carpinteria, CA). Protein A/G agarose
resin was purchased from Pierce (Rockford, IL).
Cell Culture
Porcine aortic endothelial cells transfected with the KDR
receptor (PAE/KDR) or the FLT-1 receptor (PAE/FLT-1)
were a generous gift from Dr. J. Waltenberger. MDA-MB-
231 cells were a generous gift from Dr. Janet Price. MDA-
MB-231, MDA-MB-435, PAE/KDR, and PAE/FLT-1 cells
were maintained as a monolayer in F12 Nutrient Media
(HAM) supplemented with 100 U/ml penicillin, 100 U/ml
streptomycin, and 10% fetal bovine serum. SK-BR3 cells
were maintained in RPMI 1640 media supplemented with
100 U/ml penicillin, 100 U/ml streptomycin, and 10% fetal
bovine serum. BT474 cells were maintained in SK-BR3
media supplemented with 5 mg/ml insulin. Cells were har-
vested by treatment with Versene (0.02% EDTA) or trypsin–
EDTA. Tumor cells intended for injection into mice were
washed once and resuspended in serum-free medium with-
out supplements. Cell number and viability were determined
by staining with 0.2% trypan blue dye diluted in saline. Only
single-cell suspensions of greater than 90% viability were
used for in vivo studies.
Expression and Purification of VEGF121/rGel
The construction, expression, and purification of VEGF121/
rGel have been previously described [38]. The fusion toxin
was stored in sterile PBS at 20jC.
Cytotoxicity of VEGF121/rGel and rGel
The cytotoxicity of VEGF121/rGel and rGel against log
phase PAE/KDR and PAE/FLT-1 cells has been previously
described [38]. Here, we assessed the cytotoxicity of
VEGF121/rGel and rGel against log phase human breast
cancer cells and compared their cytotoxicity to PAE/KDR
cells. Cells were grown in 96-well flat-bottom tissue culture
plates. Purified VEGF121/rGel and rGel were diluted in cul-
ture media and added to the wells in five-fold serial dilutions.
Cells were incubated for 72 hours. The remaining adherent
cells were stained with crystal violet (0.5% in 20% methanol)
and solubilized with Sorenson’s buffer (0.1 M sodium cit-
rate, pH 4.2 in 50% ethanol). Absorbance was measured
at 630 nm.
Western Blot Analysis
Whole cell extracts were obtained by lysing cells in cell
lysis buffer (50 mM Tris, pH 8.0, 0.1 mM EDTA, 1 mM DTT,
12.5 mMMgCl2, 0.1 M KCl, and 20% glycerol) supplemented
with protease inhibitors [leupeptin (0.5%), aprotinin (0.5%),
and PMSF (0.1%)]. Protein samples were separated by
SDS-PAGE under reducing conditions and electrophoreti-
cally transferred to a PVDF membrane overnight at 4jC in
transfer buffer (25 mM Tris–HCl, pH 7.6, 190 mM glycine,
and 20% HPLC-grade methanol). The samples were ana-
lyzed for KDR with rabbit anti-KDR polyclonal antibody
and FLT-1 using an anti–FLT-1 polyclonal antibody. The
membranes were then incubated with goat antirabbit IgG
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horseradish peroxidase (HRP), developed using the ECL de-
tection system (Amersham Pharmacia Biotech) and exposed
to X-ray film.
Immunoprecipitation
Cells were lysed as described above. Five hundred micro-
grams of whole cell lysates of MDA-MB-231, MDA-MB-435,
BT474, and SK-BR3 cells was mixed with 2 mg of anti-KDR or
anti–FLT-1 polyclonal antibodies in a final volume of 250 ml
and incubated for 2 hours at 4jC. One hundred micrograms
of PAE/KDR and PAE/FLT-1 cell lysates was immunopreci-
pitated as controls. The mixtures were then incubated for
2 hours with Protein A/G agarose beads that had been
blocked with 5% BSA. The beads were washed four times
in lysis buffer and the samples, along with 30 mg of PAE/KDR
cell lysate, were run on a gel, transferred overnight onto
a PVDF membrane, and probed using anti-KDR or anti–
FLT-1 antibodies.
Isolation of RNA and Reverse Transcription Polymerase
Chain Reaction (RT-PCR) Analysis
Total RNA was extracted using the RNeasy mini-kit
(Qiagen, Valencia, CA) and its integrity was verified by
electrophoresis on a denaturing formaldehyde agarose gel.
RT-PCR analysis was performed using the following primers:
KDR forward—5V ATTACTTGCAGGGGACAG; KDR re-
verse—5V GGAACAAATCTCTTTTCTGG; FLT-1 for-
ward—5V CAAATGCAACGTACAAAGA; FLT-1 reverse—5V
AGAGTGGCAGTGAGGTTTTT; GAPDH forward—5VGTC-
GTCTTCACCACCATGGAG; and GAPDH reverse—5V CC-
ACCCTGTTGCTGTAGC. Isolated RNA was subjected to
first-strand cDNA synthesis as described by the manu-
facturer of the Superscript First Strand synthesis system
(Invitrogen, Carlsbad, CA). RT-PCR was performed using
a Minicycler PCR machine (MJ Research, Inc., San Fran-
cisco, CA).
Localization of VEGF121/rGel to Blood Vessels of
MDA-MB-231 Lung Metastatic Foci
All animal experiments were carried out in accordance
with institutional guidelines and protocols. Tumor cells
(5  105 per mouse) were injected intravenously (i.v.) and,
4 to 5 weeks later, the mice began to show signs of
respiratory distress. At this time, the mice were injected i.v.
with VEGF121/rGel (50 mg/mouse) or free rGel (20 mg/mouse,
molar equivalent to VEGF121/rGel). One hour later, the mice
were sacrificed and exsanguinated. All major organs and
tumor were harvested and snap-frozen for the preparation
of cryosections. Frozen sections were double-stained with
anti–CD-31 (5 mg/ml) followed by detection of the localized
fusion protein using rabbit antigelonin antibody (10 mg/ml).
CD-31 rat IgG was visualized by goat antirat IgG conjugated
to Cy-3 (red fluorescence). Rabbit antigelonin antibody was
detected by goat antirabbit IgG conjugated to FITC (green
fluorescence). Colocalization of both markers was indicated
by the yellow color. Anti-rGel antibody had no reactivity
with tissues sections derived from mice injected with saline
or with VEGF121.
Metastatic Model of MDA-MB-231 Tumors
A maximum tolerated dose of 45 mg/kg for VEGF121/rGel
under the conditions described below was established. For
treatment purposes, 70% of the MTDwas used. We currently
demonstrate a comparison with a diluent (saline) control as
previous studies have demonstrated no impact of free rGel
on the growth of tumor xenografts [38]. Female SCID mice,
aged 4 to 5 weeks, were injected in a tail vein with 0.1 ml of
MDA-MB-231 cell suspension (5 105 cells). The mice were
randomly separated into two groups (six mice per group) and
were treated with either VEGF121/rGel or rGel starting on the
eighth day after the injection of cells. VEGF121/rGel was
delivered at 100 mg/dose intraperitoneally, for a total of six
times, with the interval of 3 days. The molar equivalent of
rGel (40 mg) was delivered at the same schedule. Intraperi-
toneal, rather than intravenous, injection was chosen solely
to prevent necrosis of the tail vein due to repeated injections.
Animal weight was monitored. Three weeks after termination
of the treatment, the animals were sacrificed and their lungs
were removed. One lobe was fixed in Bouin’s fixative and
the other lobe was snap-frozen. After fixation in Bouin’s fixa-
tive, the tumor colonies on the lung surface appeared white,
whereas the normal lung tissue appeared brown. The number
of tumor colonies on the surface of each lung was counted
and the weight of each lung was measured. The values ob-
tained from individual mice in the VEGF121/rGel and rGel
groups were averaged per group.
Determination of the Number, Size, and Vascular Density
of Lung Metastatic Foci
Frozen samples of lung tissue were cut to produce
sections of 6 mm. Blood vessels were visualized by MECA
32 antibody and metastatic lesions were identified by mor-
phology and w6/32 antibody, directed against human HLA
antigens. Each section was also double-stained by MECA
32 and w6/32 antibodies to ensure that the analyzed blood
vessels are located within a metastatic lesion. Slides were
first viewed at low magnification (2 objective) to determine
the total number of foci per cross section. Six slides derived
from individual mice in each group were analyzed and the
number was averaged. Images of each colony were taken
using a digital camera (CoolSnap) at magnifications of 40
and 100, and analyzed using Metaview software, which
allows measurements of the smallest and largest diameter,
perimeter (mm), and area (mm2). The vascular endothelial
structures identified within a lesion were counted and the
number of vessels per each lesion was determined and
normalized per square millimeter. The mean number of
vessels per square millimeter was calculated per slide
and averaged per VEGF121/rGel and rGel groups (six slides
per group). The results are expressed as ±SEM. The same
method was applied to determine the mean number of ves-
sels in nonmalignant tissues.
Immunohistochemical Analysis of Proliferation of Tumor
Cells in Lung Colonies
Frozen sections of mouse normal organs and metastatic
lungs were fixed with acetone for 5 minutes and rehydrated
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with PBS-T for 10 minutes. All dilutions of antibodies were
prepared in PBS-T containing 0.2% BSA. Primary antibodies
were detected by appropriate antimouse, antirat, or antirabbit
HRP conjugates. HRP activity was detected by developing
with DAB substrate (Invitrogen, Carlsbad, CA). To determine
number of cycling cells, sections were stained with the Ki-67
antibody followed by antimouse IgG HRP conjugate. Sec-
tions were analyzed at a magnification of 100. The number
of cells positive for Ki-67 was normalized per square millime-
ter. The mean ± SD per VEGF121/rGel and control group is
presented. The average numbers derived from analysis of
each slide were combined per either VEGF121/rGel or rGel
group and analyzed for statistical differences.
Expression of Flk-1 in Metastatic Lung Tumors
The expression of Flk-1 on the vasculature of breast
tumors metastatic to the lungs was also assessed using the
RAFL-1 antibody as described by Ran et al. [45]. Frozen
sections of lungs frommice treated with VEGF121/rGel or free
gelonin stained with monoclonal rat antimouse VEGFR-2
antibody RAFL-1 (10 mg/ml). RAFL-1 antibody was detected
by goat antirat IgG HRP.
Statistical Analysis
Results are expressed as mean ± SEM, unless otherwise
indicated. Statistical significance was determined by one-
way analysis of variance followed by the Student’s t test.
Results
Expression of KDR and FLT-1 RNA and Protein in Breast
Cancer Cell Lines
Because VEGF121 binds only to KDR and FLT-1, we first
examined RNA and protein levels of these two receptors in
several breast cancer cell lines: BT474, MDA-MB-231, MDA-
MB-435, and SK-BR3. Total RNA was harvested from log
phase cells, analyzed for integrity, and subjected to RT-PCR
with primers KDR, FLT-1, and GAPDH (control). KDR and
FLT-1 were immunoprecipitated from whole cell extracts and
identified by Western blot analysis. PAE/KDR and PAE/
FLT-1 cells were used as positive controls. None of the breast
cancer cell lines expressed detectable levels of FLT-1RNAor
protein as determined by RT-PCR and Western blot analysis
(data summarized in Table 1). RT-PCR analysis of MDA-MB-
231 showed extremely low levels of KDR compared to PAE/
KDR. However, MDA-MB-231 cells did not express detect-
able amounts of KDR protein. The other breast cell lines did
not express detectable amounts of KDR RNA or protein.
Cytotoxicity of VEGF121/rGel on MDA-MB-231 Cells
We have previously demonstrated that VEGF121/rGel is
cytotoxic to endothelial cells expressing KDR but not FLT-1
[38]. As assessed byWestern blot, none of the breast cancer
cell lines examined appears to express FLT-1 or KDR—the
receptors that bind VEGF121. We additionally examined the
cytotoxicity of VEGF121/rGel and rGel on these breast
cancer cell lines. BT474, MDA-MB-435, and SK-BR3 all
show a slightly lower IC50 for VEGF121/rGel compared to
rGel alone. In contrast, MDA-MB-231 cells in culture showed
an IC50 slightly higher than that observed for recombinant
gelonin (Table 1 and Figure 1), indicating that VEGF121/rGel
does not have a specific target on MBA-MB-231 cells. The
IC50 of untargeted rGel toward MDA-MB-231 cells is similar
to its IC50 toward PAE/KDR cells (Figure 1). Compared to the
IC50 of VEGF121/rGel toward PAE/KDR cells (1 nM), the IC50
of VEGF121/rGel toward the breast cancer cell lines exam-
ined was much higher, ranging from 30 to 300 nM. Indeed,
the IC50 of VEGF121/rGel toward these breast cancer cell
lines was in the IC50 range of untargeted rGel toward the
PAE/KDR cells. Taken together, these in vitro data suggest
that MDA-MB-231 tumor cells are not specifically targeted by
VEGF121/rGel, and that any in vivo effect on the growth of
tumors would be due to VEGF121/rGel targeting the tumor
vasculature rather than the tumor cells themselves.
Localization of VEGF121/rGel to the Vasculature of
MDA-MB-231 Lung Metastatic Foci
Mice bearing metastatic MDA-MB-231 tumors were
injected intravenously with either VEGF121/rGel or free rGel
and, 1 hour later, the mice were exsanguinated. Frozen
sections were prepared from the lung tumor foci and normal
organs, and examined immunohistochemically to determine
the location of the free rGel and the gelonin fusion construct.
VEGF121/rGel was primarily detected on the endothelium of
tumor (Figure 2). Vessels with bound VEGF121/rGel were
homogeneously distributed within the tumor vasculature.
No VEGF121/rGel staining was detected in any of the normal
tissues examined (lung, liver, kidney, heart, spleen, pan-
creas, and brain; data not shown). Free rGel did not localize
to tumor or normal vessels in any of the mice, indicating
that only targeted rGel was able to bind to the tumor
Table 1. Correlation between the Presence of VEGF121 Receptors and Sensitivity to VEGF121/rGel.
Cell Type RT-PCR Immunoprecipitation IC50 (nM) Targeting Index*
KDR FLT-1 KDR FLT-1 VEGF121/rGel rGel
BT474     300 2000 7
MDA-MB-231 +    150 40 0.3
MDA-MB-435     56 327 6
SK-BR3     200 500 2.5
*Targeting index is defined as (IC50 rGel)/(IC50 VEGF121/rGel).
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endothelium. These results indicate that VEGF121/rGel spe-
cifically localizes to tumor vessels, which demonstrate a high
density and a favorable distribution of the VEGF121/rGel–
binding sites.
MDA-MB-231 Model of Experimental Pulmonary
Metastases and Rationale for Therapeutic Regimen
Human breast carcinoma MDA-MB-231 cells consistently
lodge in lungs following intravenous injection into the tail vein
Figure 2. VEGF121/rGel localizes to the vasculature of breast tumor foci in the lungs of mice. Female SCID mice were injected i.v. with 0.1 ml of MDA-MB-231 cell
suspension (5  105 cells) as described in the Materials and Methods section. Six weeks later, mice were administered one dose (i.v., tail vein) of 100 g of
VEGF121/rGel. Four hours later, the mice were sacrificed and the tumor-bearing lungs were fixed. Tissue sections were stained for blood vessels using the anti –
CD-31 antibody (red) and the section was counterstained using an antigelonin antibody (green). Colocalization of the stains (yellow) demonstrates the presence of
the VEGF121/rGel fusion construct specifically in blood vessels and not on tumor cells.
Figure 1. MDA-MB-231 cells are not targeted by VEGF121/rGel due to the lack of expression of VEGFR-2/KDR. (A) Western analysis demonstrating the presence
of KDR on endothelial cells transfected with the KDR receptor (PAE/KDR) but not on cells expressing the FLT-1 receptor (PAE/FLT-1, negative control). As shown,
the MDA-MB-231 cells did not express detectable amounts of KDR. (B) Log phase MDA-MB-231 and PAE/KDR cells were treated with various doses of VEGF121/
rGel or rGel for 72 hours. VEGF121/rGel was far more toxic than rGel toward PAE/KDR cells (IC50 of 1 vs 100 nM). In contrast, the cytotoxic effects of both agents
were similar toward MDA-MB-231 cells (IC50 of 150 nM with VEGF121/rGel vs 40 nM with rGel), demonstrating no specific cytotoxicity of the fusion construct
compared to free toxin on these cells.
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of athymic or SCID mice. Micrometastases are first detected
3 to 7 days after injection of 5  105 cells, and macroscopic
colonies develop in 100% of the injected mice within 4 to
7 weeks. Mortality occurs in all mice within 10 to 15 weeks.
This model of experimental breast cancer metastasis exam-
ines the ability of tumor cells to survive in the blood circula-
tion, extravasate through the pulmonary vasculature, and
establish growing colonies in the lung parenchyma.
We evaluated the effect of VEGF121/rGel on the growth
and survival of the established micrometastases. We, there-
fore, started the treatment 8 days after injection of the tumor
cells. By that time, based on our prior observations, tumor
cells that were able to survive in the circulation and traverse
the lung endothelial barrier are localized within the lung pa-
renchyma and initiate tumor angiogenesis. Treatment with
VEGF121/rGel was given intraperitoneally for the following
3 weeks as described under the Materials and Methods
section, with the mice receiving 70% of the maximum toler-
ated accumulative dose of the drug (900 mg/mouse). Prior
studies established that the VEGF121/rGel given at such
dose did not cause histopathologic changes in normal
organs. The accumulative dose of total VEGF121/rGel fu-
sion protein did not induce significant toxicity as judged by
animal behavior morphologic evaluation of normal organs.
Transient loss of weight (f10%) was observed 24 hours
after most of the treatments with complete weight recovery
thereafter. Colonies were allowed to expand in the absence
of treatment for the following 3 weeks to evaluate the long-
term effect of VEGF121/rGel on the size of the colonies,
proliferation index of tumor cells, and their ability to induce
new blood vessel formation.
Effect of VEGF121/rGel on the Number and Size of
MDA-MB-231 Tumor Lesions in Lungs
An antibody directed against human HLA was used to
identify metastatic lesions of MDA-MB-231 cells on samples
of lung tissue. Treatment with VEGF121/rGel, but not with free
rGel, significantly reduced by between 42%and 58%both the
number of colonies per lung and the size of the metastatic
foci present in the lung, as shown in Figure 3 and Table 2.
Effect of VEGF121/rGel on the Vascularity of MDA-MB-231
Pulmonary Metastatic Foci
Blood vessels were visualized by MECA 32 antibody. The
overall mean vascular density of lung colonies was reduced
by 51% compared to the rGel-treated controls (Table 3 and
Figure 4); however, the observed effect was nonuniformly
distributed by tumor colony size. The greatest impact on vas-
cularization was observed on mid-sized and extremely small
tumors (62% and 69% inhibition, respectively), whereas large
tumors demonstrated the least effect (10% inhibition). The
majority of lesions in the VEGF121/rGel–treated mice (f70%)
was avascular, whereas only 40% of lesions from the control
group did not have vessels within the metastatic lung foci.
Effect of VEGF121/rGel on the Number of Cycling Cells
in the Metastatic Foci
The growth rate of MDA-MB-231 cells was determined by
staining cells with Ki-67 antibody, as described. The number
of cycling tumor cells in lesions from the VEGF121/rGel group
was also reduced byf60% compared to controls (Figure 5).
This finding suggests that the vascularity of metastases
directly affects tumor cell proliferation.
Figure 3. VEGF121/rGel reduces number of large colonies in the metastatic lungs. The size of tumor colonies was analyzed on slides stained with w6/32
antibody, which specifically recognizes human HLA antigens. The antibody delineates colonies of human tumor cells and defines borders between metastatic
lesions and mouse lung parenchyma. The largest size differences between VEGF121/rGel and control groups were found in groups of colonies having diameters
either less than 50 m or more than 1000 m. In the VEGF121/rGel – treated mice, more than 40% of total foci was extremely small (<50 m) compared to 18% in
the control group. The control mice had approximately 8% of the extremely large colonies (>1000 m), whereas VEGF121/rGel – treated mice did not have
colonies of this size.
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Effect of VEGF121/rGel on Flk-1 Expression in Tumor
Vessel Endothelium
The expression of Flk-1 on the remaining few vessels
present in lung metastatic foci demonstrated a significant
decline compared to that of lung foci present in control tumors
(Figure 6). This suggests that the VEGF121/rGel agent is able
to significantly downregulate the receptor or prevent the
outgrowth of highly receptor-positive endothelial cells.
Discussion
Neovascularization is a particularly important hallmark of
breast tumor growth and metastatic spread [46–50]. The
growth factor VEGF-A and the receptor KDR have both been
implicated in highly metastatic breast cancers [51–53]. We
have previously demonstrated that the VEGF121/rGel growth
factor fusion toxin specifically targets Flk-1/KDR–expressing
tumor vascular endothelial cells and inhibits the growth of
subcutaneously implanted human tumor xenografts [38].
The current study was designed to evaluate its effect on
the development of breast cancer metastases in lungs fol-
lowing intravenous injection of MDA-MB-231 cells.
The salient finding of our study of the VEGF121/rGel
construct is that: this fusion toxin is specifically cytotoxic to
cells overexpressing the KDR receptor for VEGF. However,
the human breast MDA-MB-231 cells employed for these
studies do not express this receptor and, therefore, were not
directly affected by this agent (Figure 1). Although the
antitumor effects of VEGF121/rGel observed from our in vivo
studies appear to be solely the result of targeting the Flk-1–
expressing tumor vasculature and not the tumor cells them-
selves, one cannot rule out a direct effect on tumor cells or a
combination of targeting both the tumor and the vasculature.
Administration of the VEGF121/rGel construct to mice previ-
ously injected (i.v.) with tumor cells dramatically reduced the
number of tumor colonies found in the lung, their size, and
their vascularity. In addition, the number of cycling breast
tumor cells within lung metastatic foci was found to be
reduced by an average of 60%. This reduction compares
favorably to the effect of DT-VEGF on the growth of pancre-
atic cancer [54] and to other vascular targeting agents such
as Avastin, which had an overall clinical response rate of
9.3% in a Phase I/II dose escalation trial in previously treated
metastatic breast cancers [55]. In addition to the reduced
number of blood vessels present in lung metastases of
treated mice, we also found that the few vessels present
Table 3. Effect of VEGF121/rGel on the Vascularity of Pulmonary Metastases of MDA-MB-231 Human Breast Carcinoma Cells.
Size of Colonies Largest Diameter
Range (mm)
Number of Vascularized Colonies from
Total Inhibition Analyzed (%)*
% Inhibition versus
Radiation Treatment
Groupy Description rGel VEGF121/rGel
A Extremely small <50 7/24 (29%) 3/32 (9.3%) 69
B Small 50–200 19/48 (39.5%) 6/24 (25%) 37
C Mid-sized 200–500 25/30 (83.3%) 8/25 (32%) 62
D Large 500–1000 17/17 (100%) 10/11 (90.0%) 10
E Extremely large >1000 8/8 (100%) N/A N/A
Number of vascular
foci/total analyzed (%)z
76/127 (59.8%) 27/92 (29.3%) 51
*Frozen lung sections from VEGF121/rGel and rGel-treated mice were stained with MECA 32 antibody. A colony was defined as vascularized if at least one blood
vessel branched out from the periphery and reached a center of the lesion. Six slides per group derived from individual mice were analyzed and data were combined.
yColonies identified on each slide of a metastatic lung were subdivided into five groups (A–E) according to their largest diameter.
zThe total number of the analyzed colonies was 127 and 92 for rGel- and VEGF121/rGel – treated groups, respectively. Seventy percent of foci in the VEGF121/
rGel – treated group was a vascular, whereas only 40% of lesions from the control group did not have vessels within the metastatic foci.
Table 2. Effect of VEGF121/rGel on the Number and Size of Pulmonary
Metastases of MDA-MB-231 Human Breast Carcinoma Cells.
Parameter Treatment* % Inhibition P valuey
rGel VEGF121/rGel
versus
rGel Treatment
Number of surface
colonies per lung
(range)z
53.3 ± 22
(33–80)
22.4 ± 9.2
(11–41)
58.0 0.03
Number of
intraparenchymal
colonies per cross
section (range)§
22 ± 7.5
(18–28)
12.8 ± 5.5
(5–18)
42.0 0.02
Mean area of
colonies (mm)b
415 ± 10 201 ± 37 51.9 0.01
Mean % of
colony-occupied
area per
lung section#
57.3 ± 19 25.6 ± 10.5 55.4 0.01
*Mice with MDA-MB-231 pulmonary micrometastases were treated intra-
peritoneally with VEGF121/rGel or free gelonin as described under Materials
and Methods and Results sections.
yP value was calculated using Student’s t test.
zLungs were fixed with Bouin’s fixative for 24 hours. The number of surface
white colonies was determined for each sample and averaged among six
mice from VEGF121/rGel or rGel control group. Mean number per group
±SEM is shown. Numbers in parentheses represent the range of colonies in
each group.
§Frozen sections were prepared from metastatic lungs. Sections were stained
with 6w/32 antibody recognizing human tumor cells. The number of intra-
parenchymal colonies identified by brown color was determined for each cross
section and averaged among six samples of individual mice from VEGF121/
rGel or rGel control group. The mean number per group ±SEM is shown.
Numbers in parentheses represent the range of colonies in each group.
bThe area of foci identified by 6w/32 antibody was measured by using
Metaview software. The total number of evaluated colonies was 101 and 79
for rGel and VEGF121/rGel group, respectively. Six individual slides per group
were analyzed. The mean area of colony in each group ±SEM is shown.
#The sum of all regions occupied by tumor cells and the total area of each lung
cross section were determined and the percentage of metastatic regions from
total was calculated. The values obtained from each slide were averaged
among six samples fromVEGF121/rGel or rGel control group. Themean percent
area occupied by metastases from the total area per group ±SEM is shown.
492 VEGF121/rGel Inhibits Pulmonary Breast Metastases Ran et al.
Neoplasia . Vol. 7, No. 5, 2005
had a greatly reduced expression of VEGFR-2. Therefore,
this construct demonstrated an impressive long-term impact
on the growth and development of breast tumor metastatic
foci found in the lungs.
Targeting tumor vasculature with a variety of technologies
has been shown to inhibit the growth and development of
primary tumors as well as metastases. Recently, Shaheen
et al. [56] demonstrated that small-molecule tyrosine kinase
inhibitors active against the receptors for VEGF, fibroblast
growth factor, and platelet-derived growth factors were also
capable of inhibiting microvessel formation and metastases
in tumor model systems. Previously, Seon et al. [57] demon-
strated long-term antitumor effects of an antiendoglin anti-
body conjugated with ricin-A chain (RTA) in a human breast
tumor xenograft model.
Surprisingly, one finding from our study was that admin-
istration of VEGF121/rGel resulted in a three-fold decrease in
the number of Ki-67– labeled (cycling) cells in the metastatic
foci present in the lung (Figure 5). Clinical studies have
suggested that tumor cell cycling may be an important
prognostic marker for disease-free survival in metastatic
breast cancer, but that Ki-67 labeling index, tumor MVD,
and neovascularization appear to be independently regu-
lated processes [58,59]. To our knowledge, this is the first
report of a significant reduction in tumor labeling index
produced by a vascular targeting agent.
Another critical finding from our studies is the observa-
tion that the vascular-ablative effects of the VEGF121/rGel
fusion construct alone were unable to completely eradicate
lung metastases. Although the growth of larger pulmonary
Figure 5. VEGF121/rGel inhibits the proliferation of metastatic MDA-MB-231
cells in the lungs. Frozen sections of lungs derived from VEGF121/rGel and
rGel-treated mice were stained with Ki-67 antibody. Stained sections were
examined under 40 objective to determine the number of tumor cells with
positive nuclei (cycling cells). Positive cells were enumerated in 10 colonies
per slide on six sections derived from individual mice per treatment group.
The mean number per group ±SEM is presented. VEGF121/rGel treatment
reduced the average number of cycling cells within the metastatic foci by
approximately 60%.
Figure 4. VEGF121/rGel inhibits the vascularization of MDA-MB-231 pulmonary metastases. (A) Lungs derived from VEGF121/rGel and rGel-treated mice were
stained with MECA 32 antibody and the vascular density within the metastatic foci was determined. The mean number of vessels per square millimeter in lung
metastases of VEGF121/rGel – treated mice was reduced by approximately 50% compared to those in rGel-treated mice. (B) Representative images demonstrating
reduction of vascular density in foci of comparable size in mice treated with rGel (left) and VEGF121/rGel fusion protein (right).
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metastases was completely inhibited by this therapeutic ap-
proach, the development of small, avascular, metastatic foci
within lung tissues was observed. Our findings indicate that
vasculature in the small and mid-sized metastatic lesions
(diameter < 500 mm) was much more susceptible to the
action of VEGF121/rGel than that in colonies with diameters
larger than 500 mm. Several explanations might account for
this observation. First, the number of VEGF receptors on
endothelial cells within the small, exponentially expanding
colonies might be higher than that in the well-established
lesions. This would lead to an increase in binding sites for
VEGF121/rGel and, hence, an increased toxicity toward
vessels specifically in small colonies. Second, vascular
endothelial cells in small colonies might have a reduced
capacity to survive after drug assault compared to vessels
in established lesions. This could be due to insufficient
recruitment of supporting cells (pericytes/smooth muscle
cells) to the newly formed vessels, and/or derangements in
the production of and interaction with components of base-
ment membrane. Currently, the precise mechanism of the
differential anti–vascular toxicity on different size colonies is
not completely understood. However, these data strongly
suggest that the combination of vascular targeting agents
with chemotherapeutic agents or with radiotherapeutic
agents, which directly damage tumor cells themselves,
may provide for greater therapeutic effect. Studies of several
vascular targeting agents in combination with chemothera-
peutic agents have already demonstrated a distinct in vivo
antitumor advantage of this combination modality against
experimental tumors in mice [60]. Studies by Pedley et al.
[61] have also suggested that the combination of vascular
targeting and radioimmunotherapy may also present a po-
tent antitumor combination. Finally, studies combining hyper-
thermia and radiotherapy with vascular targeting agents
have demonstrated an enhanced activity against mammary
carcinoma tumors in mice [62]. Studies in our laboratory
combining VEGF121/rGel and various chemotherapeutic
agents, biologic agents, or therapeutic agents targeting
tumor cells are currently ongoing.
The rGel toxin is a single-chain N-glycosidase that is
similar in its action to ricin-A chain [39]. However, unlike
ricin-A chain, the use of rGel does not appear to result in
VLS [44]. Side effects have been observed with clinical
administration of RTA-based, diphtheria toxin–based, and
Pseudomonas exotoxin–based fusion proteins. These side
effects include liver toxicity, development of neutralizing anti-
bodies, and development of VLS. The development of neu-
tralizing antibodies was found in 69% of patients treated with
RTA immunotoxins [63], 37% of patients treated with PE-
based constructs [64], and 92% of patients treated with DT
constructs [65]. In contrast, our ongoing clinical trial with an
rGel-based conjugate currently demonstrates a relatively low
antigenicity of the rGel component, with only 2 of 22 patients
developing antibodies to the rGel portion of the drug [44]. In
addition, the development of hepatoxicity and VLS is com-
monly observed, with toxin molecules thus far not having
been observed for rGel-based agents. These findings sup-
port continuing development in a clinical setting of targeted
therapy using rGel. In addition, our laboratory continues to
develop designer toxins with reduced antigenicity and size [66].
The presented findings demonstrate that VEGF121/rGel
can clearly and specifically target Flk-1/KDR–expressing
tumor vasculature both in vitro and in vivo and that this agent
can have an impressive inhibitory effect on tumor metas-
tases. Studies are continuing in our laboratory to examine
the activity of this agent alone and in combination against
a variety of orthotopic and metastatic tumor models.
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